

ADAKVEO
(crizanlizumab-tmca)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 16 years of age or older

Diagnosis

Patient must have the following:

Vasoocclusive crises associated with Sickle Cell Disease (SCD)

AND ALL of the following:

1. Adakveo will be administered by a healthcare professional
2. Prescriber agrees to monitor for infusion-related reactions
3. Prescriber agrees to monitor for the development of late evolving antibodies

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 16 years of age or older

Diagnosis

Patient must have the following:

Vasoocclusive crises associated with Sickle Cell Disease (SCD)

AND ALL of the following:

1. Reduction in the number of vasoocclusive crises since initiating therapy
2. Adakveo will be administered by a healthcare professional
3. Prescriber agrees to monitor for infusion-related reactions
4. Prescriber agrees to monitor for the development of late evolving antibodies



**BlueCross
BlueShield**

Federal Employee Program.

**ADAKVEO
(crizanlizumab-tmca)**

Prior - Approval *Renewal* Limits

Same as above